Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

Mednews Week | <b>Oncology Unplugged With Dr Chandler Park</b>

Chandler Park, MD, talks through key updates in genitourinary cancer research from the 2024 ESMO Congress.

In Oncology Unplugged, a podcast series from MedNews Week, host Chandler Park, MD, a medical oncologist at the Norton Cancer Institute in Louisville, Kentucky, talks through key updates in genitourinary cancer research from the 2024 ESMO Congress.

In this episode, Dr Park highlights potentially practice-changing data in prostate, kidney, and bladder cancer; spotlights the potential clinical implications of findings with the intravesical therapy TAR-200 in patients with muscle-invasive bladder cancer (MIBC); and zooms in on data from the phase 3 NIAGARA trial (NCT03732677) of durvalumab (Imfinzi) plus gemcitabine and cisplatin in patients with MIBC.